PERSPECTA

News from every angle

← Back to headlines

LeonaBio Exceeds Q2 Loss Forecast as ELAINE-3 Trial Progresses

LeonaBio has surpassed its second-quarter loss forecast, indicating better-than-expected financial performance. This positive outcome is attributed to the advancement of its Phase 3 ELAINE-3 trial.

17 Aug, 12:26 — 17 Aug, 12:26
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual9d ago

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

Read full article →

Coverage Timeline

First report: investing-com · 17 Aug, 10:26Full coverage: 2 · 2hWindow: 2h
Left-leaningCenterRight-leaning
investing-com17 Aug, 10:26First to report

LeonaBio beats second quarter loss estimates - Investing.com

2h later
Yahoo17 Aug, 12:26Latest update

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

Related Stories

BOJ Deputy Governor Urges Timely Interest Rate Hike Amid Inflation Pressures

17m ago

Asian Markets Show Mixed Gains as Nvidia Outlook Offsets Inflation Concerns

25m ago

Belgrade Prepares Tender for 85 New Trams Amid Early Concerns

31m ago

Energy Sector Firms Report Strong Financial Performance for Early 2026

36m ago